PROTEASE INHIBITORS

	Nucleoside and Nucleotide reverse transcriptase inhibitors		Protease inhibitors
	Non-Nucleoside reverse transcriptase inhibitors		Fusion inhibitors

	Mutations associated to resistance	Mutations associated to « possible resistance »
IDV	M46I/L V82A/F/M/S/T [11] I84A/V [8] L90M and at least 2 mutations among : K20M/R, L24I, V32I, M36I, I54V/L/M/T, A71V/T, G73S/A, V77I	L90M
SQV/RTV 800/100 mg BID	G48V At least 2 mutations among L24I, I62V, V82A/F/T/S, I84V, L90M [9]
NFV	D30N I84A/V [8] N88S/D L90M	V82A/F/S/T and at least 2 mutations among: L10I, M36I, M46I/L, I54V/L/M/T, A71V/T, V77I [1]
fosAPV/RTV 700/100 mg BID	I50V At least 6 mutations among: L10F/I/V, K20M/R, E35D, R41K, I54V, L63P, V82A/F/S/T, I84V [2, 12] V32I and I47V [13, 14]
LPV/r	At least 8 mutations among : L10F/I/R/V, K20M/R, L24I, L33F, M46I/L, I50V, F53L, I54M/L/T/V, L63P, A71I/L/V/T, V82A/F/S/T, I84V, L90M [3, 4, 5] V32I and I47A [15]	6 or 7 mutations among: L10F/I/R/V, K20M/R, L24I, L33F, M46I/L, I50V, F53L, I54M/L/T/V, L63P, A71I/L/V/T, V82A/F/S/T, I84V, L90M [3, 4, 5]
ATV/RTV 300/100 mg QD	I50L [6] At least  3 mutations among: L10F/I/V, G16E, L33F/I/V, M46I/L, D60E, I84V, I85V, L90M [7]
TPV/RTV 500/200 mg BID	At least 8 mutations among: L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D, I84V [10]	4, 5, 6 or 7 mutations among: L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D, I84V [10]